KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Share-based Compensation (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Share-based Compensation for 18 consecutive years, with $257.4 million as the latest value for Q1 2026.

  • For Q1 2026, Share-based Compensation rose 0.66% year-over-year to $257.4 million; the TTM value through Mar 2026 reached $995.4 million, down 1.29%, while the annual FY2025 figure was $993.7 million, 1.11% up from the prior year.
  • Share-based Compensation hit $257.4 million in Q1 2026 for Regeneron Pharmaceuticals, up from $249.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $304.4 million in Q4 2024 and bottomed at $159.8 million in Q2 2022.
  • Average Share-based Compensation over 5 years is $226.1 million, with a median of $232.0 million recorded in 2022.
  • Year-over-year, Share-based Compensation skyrocketed 43.02% in 2023 and then dropped 18.1% in 2025.
  • Regeneron Pharmaceuticals' Share-based Compensation stood at $232.0 million in 2022, then grew by 3.62% to $240.4 million in 2023, then rose by 26.62% to $304.4 million in 2024, then decreased by 18.1% to $249.3 million in 2025, then increased by 3.25% to $257.4 million in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $257.4 million, $249.3 million, and $237.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.